Therapeutic Effects of Mesenchymal Stem Cell Secretome Derived From Adipose Tissue, Umbilical Cord, and Bone Marrow Against Extended-Spectrum Beta-Lactamase-Producing and Non-Producing Escherichia coli Strains Isolated F
Ali L., Salem Sokhn E., Khalil C., Saleh FA.
Laboratory Study, published in FASEB J (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- FASEB J (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40635499
- DOI
- 10.1096/fj.202500758R
Abstract (original English)
Urinary tract infections (UTIs) are among the most common and persistent bacterial infections, affecting around 150 million people worldwide each year. The emergence of multidrug-resistant (MDR) strains, particularly those producing extended-spectrum β-lactamases (ESBLs), has further complicated treatment and posed a serious global public health challenge. Hence, this study aimed to investigate the antibacterial potential of mesenchymal stem cell (MSCs) secretomes derived from adipose tissue (AD-MSCs), bone marrow (BM-MSCs), and umbilical cord (UC-MSCs) against the most common cause of bacterial UTI, Escherichia coli (E. coli). The MSCs secretomes were derived from human adipose tissue, umbilical cord, and bone marrow. The antibacterial activity of the secretomes was then assessed using the Kirby-Bauer disk diffusion method. These tests were conducted on 105 E. coli urine clinical isolates, including ESBL-producing strains. Further molecular analysis was performed to identify the resistant genes. Statistical analyses were then performed to test for statistically significant differences between MSCs sources. Our results showed that the stem cell secretome was effective against 63.8% of non-ESBL and 52.7% of ESBL-producing E. coli isolates, with that derived from AD-MSCs showing the largest inhibition zones. Molecular analysis revealed that all ESBL-producing isolates (100%) harb
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.